Transposagen Wins Prestigious Tibbetts Award for Development of Genome Engineering Technology

Lexington, KY, June 16, 2015 (GLOBE NEWSWIRE)

Transposagen Biopharmaceuticals, Inc. (“Transposagen”), a privately-held biotechnology company, has accepted the highly prestigious 2015 Tibbetts Award during a White House ceremony in Washington, D.C. The U.S Small Business Administration (SBA) recognized Transposagen with the award for having leveraged Small Business Innovation Research grants from the National Institutes of Health in a way that has generated measurable value to the firm and to the nation.

Read More

Transposagen Announces Partnering Model for its Exclusive Patents Covering Rat Models of Oncology, Autoimmune and Inflammatory Diseases and Issuance of OncoRat™ Registered Trademark

Lexington, KY, April 16, 2015 (GLOBE NEWSWIRE)

Transposagen, a world leader in genome engineering technologies and services, announced the registration of its trademark OncoRat™ by the USPTO, for use with rat models for oncology in issued patent No. 8,722,964. OncoRat™ covers all genetically engineered rat models with oncology phenotypes, regardless of the method used to create the rat model (e.g. site-specific nucleases, homologous recombination, transposon insertion, etc.).

Read More

Stemgent, a ReproCELL Group Company and Transposagen Biopharmaceuticals Enter into a Service Partnership Agreement Providing Genetically Engineered Stem Cells

Stemgent, Inc., A ReproCELL Group Company (Cambridge, Massachusetts, U.S.A) and Transposagen Biopharmaceuticals Inc. (Lexington, Kentucky, USA) announced they have entered into a partnership agreement enabling the development of genetically engineered induced pluripotent stem cells (iPSC) services for pharmaceutical, biotechnology, academic and government organizations. 

Read More

Transposagen Biopharmaceuticals Enters into Research Collaboration and Worldwide License Agreement with Janssen for Allogeneic Chimeric Antigen Receptor (CAR) T-Cell Therapies

Transposagen Biopharmaceuticals, Inc., (Transposagen) a private biotechnology company headquartered in Lexington, KY, today announced they have entered into a research collaboration and worldwide license agreement with Janssen Biotech, Inc. (Janssen) to develop allogeneic Chimeric Antigen Receptor T-cells (CAR-T). To date, CAR-T therapies have shown promise in early human clinical trials for the treatment of blood cancers and allogeneic CAR-Ts have the potential for use as off-the-shelf cancer treatments without the need of matching donor with recipient.

Read More

Transposagen's NextGEN™ CRISPR Technology Promises Clean Genome Editing without Off-Target Mutations

Altering the genome with targeted nucleases is powerful and increasingly necessary for research and drug discovery. The CRISPR-Cas9 system has gained popularity due to its simplicity and high efficiency. However, the CRISPR technology has been plagued by problems with off-target mutations, a concern for research and drug discovery applications as it may compromise results.

Read More